Company Overview
We are united in our mission to develop and deliver transformative therapies that reverse fibrosis, restore health and improve the lives of patients worldwide.
Company Overview
Thendor Therapeutics is an early-stage company focused on building a development pipeline for fibrotic diseases by investigating the mechanisms that drive pathological scarring and organ dysfunction. Our peptide-based approach focuses on discovery and development of therapeutic candidates that may to restore balance to tissue repair and improve long-term patient outcomes.
Via our subsidiary, ThendUro, we apply this science to urological fibrosis, advancing therapeutic candidates under development.
Via our subsidiary, ThendUro, we apply this science to urological fibrosis, advancing therapeutic candidates under development.
Why We Are Here
Founded in 2023, we’re building a modern antifibrotic biotech model, one grounded in peptide innovation, focused subsidiaries, and purposeful execution.
Designed for Multi-Organ Fibrosis
We focus on shared pathways that drive fibrosis across lung, skin, and urological systems.
Focused Execution Through Thenduro
Our first subsidiary, Thenduro, applies Thendor’s peptide discovery engine to urological fibrosis, demonstrating our ability to create specialized teams that drive targeted scientific progress in urological fibrosis.
Working Together for Impact
We partner with collaborators, clinicians, and scientific advisors to advance fibrosis research that may inform the development of meaningful therapies.
IMPORTANT NOTICE
We are an early stage company developing a research pipeline of products addressing fibrotic diseases. The product candidates described on this website are in various stages of development and have not been approved or determined to be safe or effective by the U.S. Food and Drug Administration or any comparable regulatory authority. Nothing on this website is intended to suggest the safety, efficacy, or commercial availability of any product candidate in the United States.